Regenerative biotechnology

CTM Biodent Osseous

Mesenchymal stem cells for advanced oral bone regeneration and optimization of implant integration.

Cellular solution containing five million placenta-derived mesenchymal stem cells, designed to stimulate alveolar bone repair, modulate the local response, and promote dental implant integration.
View technical sheet

Composition

Placenta-derived mesenchymal stem cells (5 million cells).

Pharmaceutical form

Cellular solution for regenerative surgical application.

Monovette with 4 ml.

Sterile 1 ml Monovette protected in a plastic container.

Therapeutic Properties

Biotechnological product that combines mesenchymal stem cells with demineralized bone matrix to stimulate bone regeneration and improve implant integration in oral bone defects.
  • Alveolar bone regeneration.
  • Improves dental implant integration.
  • Stimulation of local osteogenesis.
  • Reduction of oral inflammation.
  • Increase in osteocalcin.
  • Increase in osteopontin.
  • Local immunological modulation.
  • Promotes bone consolidation.

Mechanism of action & Clinical data

Mesenchymal stem cells (CTMs) secrete trophic factors and extracellular vesicles that reduce inflammation, inhibit apoptosis, and stimulate angiogenesis and bone formation at the application site.

Indications

Bone reconstruction and regeneration in dental implants, periodontal bone loss, trauma, or oral surgeries.

Administration

Local application mixed with demineralized bone matrix in the bone defect or dental surgical site.

Contraindications

Sensitivity or allergy to formula components. Diagnosis of neoplasia.

Storage

Store refrigerated between 2 and 8 °C, protected from direct sunlight. Do not freeze.
PRODUCT FOR EXCLUSIVE USE BY HEALTHCARE PROFESSIONALS. APPLICATION UNDER MEDICAL PROTOCOLS.

I want to be contacted

    CTM Biodent Osseous